Rapid Exchange Devices Observational Registry. (RXRegistry)
Prospective, Non-randomized, Multicentre, Observational Registry to Assess Clinically Relevant Benefit of Performing the Whole PTA Procedure Using the Rapid Exchange (RX) Devices.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Aalst, Belgium
- Onze-Lieve-Vrouwziekenhuis (OLV) Aalst
-
Antwerp, Belgium
- GasthuisZusters Antwerpen (GZA) Ziekenhuizen
-
Auvelais-Val de Sambre, Belgium
- Centre Hospitalier Régional (CHR) du Val de Sambre
-
Hasselt, Belgium
- Jessa Ziekenhuis
-
Liège, Belgium
- Centre Hospitalier Universitaire (CHU) Liège
-
-
-
-
-
Burgos, Spain
- Hospital Universitario de Burgos
-
Girona, Spain
- Hospital Universitari Dr. Josep Trueta de Girona
-
Santander, Spain
- Hospital Universitario Marqués de Valdecilla
-
Valladolid, Spain
- Hospital Clínico Universitario de Valladolid
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with symptomatic one or two legs ischemia, requiring treatment of SFA or popliteal artery
- Rutherford classification 2-5
- Single lesion with recoiling/dissection/restenosis after balloon angioplasty or de novo lesions with stenosis or occlusion,
- Target vessel reference diameter ≥4mm and ≤7mm (by visual estimate)
- At least one patent (less than 50% stenosis) tibioperoneal run-off vessel confirmed by baseline angiography
- Patient is suitable candidate for femoral-popliteal artery bypass surgery
Exclusion Criteria:
- Female of child-bearing potential.
- Previous bypass surgery
- In stent restenosis as a target lesion
- Scheduled staged procedure of multiple lesions within the ipsilateral iliac or popliteal arteries within 30 days after index procedure.
- Co-existing aneurysmal disease of the abdominal aorta, iliac or popliteal arteries
- Acute thrombophlebitis or deep venous thrombosis
- Hemodynamic instability
- Untreated inflow disease of the ipsilateral pelvic arteries (more than 50 percent stenosis or occlusion),
- Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy
- Known intolerance to study medications, contrast agents or nitinol.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety: composite of all-cause death, amputation, TVR, stroke or bleeding (BARC ≥ 3) up to 1 month
Time Frame: From start up to 30 Days post procedure.
|
From start up to 30 Days post procedure.
|
|
Total contrast media volume given during the procedure.
Time Frame: During procedure
|
During procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Total duration of the procedure
Time Frame: During procedure
|
During procedure
|
|
Total fluoroscopy time
Time Frame: During procedure
|
During procedure
|
|
Total radiation dose given
Time Frame: During procedure
|
During procedure
|
|
Technical success defined as a successful access and balloon angioplasty followed by stent placement with achieved recanalization determined by less than 30% residual stenosis by angiography at the baseline procedure.
Time Frame: Pre- and post-procedure
|
Pre- and post-procedure
|
|
Clinical success defined as technically successful procedure without the events considered in safety composite endpoint (all-cause death, amputation, TVR, stroke or bleeding (BARC ≥ 3) up to 1 month.
Time Frame: During procedure
|
During procedure
|
|
Total acute complication rate defined as any device- or procedure- related complication up to 1 month post procedure.
Time Frame: Up to 30 Days post procedure
|
Up to 30 Days post procedure
|
|
Total acute device related complication rate defined as any device complication up to 1 month post procedure.
Time Frame: Up to 30 Days post procedure
|
Up to 30 Days post procedure
|
|
Ankle-Brachial Index (ABI) improvement at 30 days.
Time Frame: 30 Days post procedure
|
30 Days post procedure
|
|
Improvement of the Rutherford index at 30 days.
Time Frame: 30Days post procedure
|
30Days post procedure
|
|
Walking distance at 30 days compared with walking distance before procedure.
Time Frame: 30 Days post procedure
|
30 Days post procedure
|
|
Bleeding complication as per BARC definitions.
Time Frame: Up to 30 days post procedure
|
Up to 30 days post procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Christophe Martinez, Centre Hospitalier Universitaire (CHU) Liège
- Principal Investigator: Omar Andrés Navarro, Hospital Universitari Dr. Josep Trueta de Girona
- Principal Investigator: Josua Van den Berg, Ospedale Regionale di Lugano
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- T122E2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.